ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.130
-0.070 (-5.83%)
At close: Apr 10, 2025, 4:00 PM
1.189
+0.059 (5.22%)
After-hours: Apr 10, 2025, 7:47 PM EDT
ProQR Therapeutics Revenue
In the year 2024, ProQR Therapeutics had annual revenue of 19.55M EUR with 196.41% growth. ProQR Therapeutics had revenue of 4.44M in the quarter ending December 31, 2024, with 35.29% growth.
Revenue (ttm)
19.55M EUR
Revenue Growth
+196.41%
P/S Ratio
5.11
Revenue / Employee
117,670 EUR
Employees
166
Market Cap
118.89M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19.55M | 12.95M | 196.41% |
| Dec 31, 2023 | 6.59M | 2.24M | 51.27% |
| Dec 31, 2022 | 4.36M | 1.98M | 83.31% |
| Dec 31, 2021 | 2.38M | 1.35M | 131.10% |
| Dec 31, 2020 | 1.03M | -904.00K | -46.77% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
PRQR News
- 4 weeks ago - ProQR Announces Year End 2024 Operating and Financial Results - GlobeNewsWire
- 4 months ago - ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist - GlobeNewsWire
- 5 months ago - ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewsWire
- 6 months ago - ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement - GlobeNewsWire
- 6 months ago - ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares - GlobeNewsWire
- 6 months ago - ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - GlobeNewsWire
- 7 months ago - ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 11 months ago - ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript) - Seeking Alpha